Contineum Therapeutics (CTNM) Accumulated Expenses (2023 - 2026)

Contineum Therapeutics' Accumulated Expenses history runs 4 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 139.85% year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $2.9 million, a 139.85% increase from a year earlier, with the FY2025 full-year figure at $6.4 million, down 4.83% from the prior year.
• Accumulated Expenses eased to $2.9 million in Q1 2026 per CTNM's latest filing, from $6.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $6.7 million in Q4 2024 and bottomed at $959000.0 in Q1 2024.
• The 4-year median for Accumulated Expenses is $2.5 million (2024), against an average of $3.1 million.
• Across the five-year window, Accumulated Expenses slipped 4.83% in 2025 and jumped 139.85% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $4.4 million in 2023, then jumped by 53.04% to $6.7 million in 2024, then declined by 4.83% to $6.4 million in 2025, then slumped by 55.24% to $2.9 million in 2026.
• Per Business Quant, the three latest CTNM Accumulated Expenses figures stand at $2.9 million (Q1 2026), $6.4 million (Q4 2025), and $2.8 million (Q3 2025).